Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study

References

• Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
   PubMed Web of Science ®Google Scholar
• Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A. Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016;263:1241–54.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Shefner JM, Kaji R, Burke D. Amyotrophic lateral sclerosis: a new diagnostic paradigm. J Neurol Neurosurg Psychiatry. 2020;91:903–4.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:453–6.
   PubMed Web of Science ®Google Scholar
• Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054.
   PubMed Web of Science ®Google Scholar
• Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJP, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291.
   PubMed Web of Science ®Google Scholar
• Falzone Y, Russo T, Domi T, Pozzi L, Quattrini A, Filippi M, et al. Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. Neural Regen Res. 2021;16:1985–91.
   PubMed Web of Science ®Google Scholar
• Falzone YM, Domi T, Agosta F, Pozzi L, Schito P, Fazio R, et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J Neurol. 2020;267:2272–80.
   PubMed Web of Science ®Google Scholar
• Conti E, Sala G, Diamanti S, Casati M, Lunetta C, Gerardi F, et al. Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Sci Rep. 2021;11:1978.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Gerardi F, Tarlarini C, Filippi M, Riva N, et al. Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. J Neurol. 2020;267:3609–16.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4:605–18.
   PubMedGoogle Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–38.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90:jnnp-2019-320998–7.
   Google Scholar
• Bendotti C, Bonetto V, Pupillo E, Logroscino G, Al-Chalabi A, Lunetta C, et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:485–95.
   PubMed Web of Science ®Google Scholar
• Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73:23–33.
   PubMed Web of Science ®Google Scholar
• Gentile F, Scarlino S, Falzone YM, Lunetta C, Tremolizzo L, Quattrini A, et al. The peripheral nervous system in amyotrophic lateral sclerosis: opportunities for translational research. Front Neurosci. 2019;13:601.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018; Oct14:577–89.
   PubMed Web of Science ®Google Scholar
• Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, CReATe Consortium, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020;95:e59–e69.
   PubMed Web of Science ®Google Scholar
• Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016;11:e0164625.
   PubMed Web of Science ®Google Scholar
• Li D, Shen D, Tai H, Cui L. Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta-analysis. Front Aging Neurosci 2016;8:290.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
   PubMed Web of Science ®Google Scholar
• IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
   PubMed Web of Science ®Google Scholar
• Macaskill P. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy 2010;23:12. Retrieved from https://training.cochrane.org/resource/cochrane-handbook-systematic-reviews-diagnostic-test-accuracy
   Google Scholar
• Rosengren LE, Karlsson J-E, Karlsson J-O, Persson LI, Wikkelsø C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 2002;67:2013–8.
   Google Scholar
• Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype: CSF neurofilament light levels in ALS. European Journal of Neurology. 2007;14:1329–33.
   PubMed Web of Science ®Google Scholar
• Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615–9.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Fang L, Kuhle J, Petzold A, Tumani H, Ludolph AC, et al. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One. 2011;6:e23600.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Ruggieri M, Cortese R, D'Errico E, Capozzo R, Leo A, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19:1561–7.
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8:e75091.
   PubMed Web of Science ®Google Scholar
• Menke RAL, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7):748–55.
   Google Scholar
• Pijnenburg YAL, Verwey NA, Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1:505–12.
   PubMedGoogle Scholar
• L. C-H Neurofilament light chain. 2015:11.
   Google Scholar
• Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:404–13.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, Müller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis: Biomarkers in ALS. Ann Neurol. 2016;79:152–8.
   PubMed Web of Science ®Google Scholar
• Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016;87:1270–2.
   PubMed Web of Science ®Google Scholar
• Skillbäck T, Mattsson N, Blennow K, Zetterberg H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:397–403.
   PubMed Web of Science ®Google Scholar
• Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525–32.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:112–9.
   PubMed Web of Science ®Google Scholar
• Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88:2302–9.
   PubMed Web of Science ®Google Scholar
• Pawlitzki M, Schreiber S, Bittner D, Kreipe J, Leypoldt F, Rupprecht K, et al. CSF neurofilament light chain levels in primary progressive MS: signs of axonal neurodegeneration. Front Neurol. 2018;9:1037.
   PubMed Web of Science ®Google Scholar
• Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510–21.
   PubMed Web of Science ®Google Scholar
• Illán-Gala I, Alcolea D, Montal V, Dols-Icardo O, Muñoz L, de Luna N, et al. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Neurology 2018;91:e1619–e28.
   PubMed Web of Science ®Google Scholar
• Scarafino A, D'Errico E, Introna A, Fraddosio A, Distaso E, Tempesta I, et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol. 2018;265:2353–62.
   PubMed Web of Science ®Google Scholar
• Li D-W, Ren H, Jeromin A, Liu M, Shen D, Tai H, et al. Diagnostic performance of neurofilaments in Chinese patients with amyotrophic lateral sclerosis: a prospective study. Front Neurol. 2018;9:726.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22–e30.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion: neurofilament light in presymptomatic ALS. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Gong Z-Y, Lv G-P, Gao L-N, Lu Y, Guo J, Zang D-W. Neurofilament subunit L levels in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurodegener Dis. 2018;18:165–72.
   PubMed Web of Science ®Google Scholar
• Wilke C, Rattay TW, Hengel H, Zimmermann M, Brockmann K, Schöls L, et al. Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol. 2018;5:876–82.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J, et al. Significance of CSF NfL and tau in ALS. J Neurol. 2018;265:2633–45.
   PubMed Web of Science ®Google Scholar
• Andrés-Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging (Albany NY). 2018;10:2367–82.
   PubMedGoogle Scholar
• Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76:318–25.
   PubMed Web of Science ®Google Scholar
• Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto Y, et al. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6:2489–502.
   PubMed Web of Science ®Google Scholar
• Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C, et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 2019;92(11):e1205–e1211.
   PubMed Web of Science ®Google Scholar
• Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157–64.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:538–48.
   PubMed Web of Science ®Google Scholar
• Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45:291–304.
   PubMed Web of Science ®Google Scholar
• Yang B, Wu Y, Wang Y, Yang H, Du B, Di W, et al. Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis. Neurol Sci. 2020;41:2915–20.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Han Y, Song Y, Gao Y. Correlational analysis of ALS progression and serum nfl measured by simoa assay in Chinese patients. Front Neurol. 2020;11:579094.
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhao X, Li S, Yang F, Wang H, Cui F, et al. CSF neurofilament light chain elevation predicts ALS severity and progression. Front Neurol. 2020;11:919.
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Vacchiano V, Zenesini C, Polischi B, de Pasqua S, Fileccia E, BoReALS, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J Neurol. 2020;267:1699–708.
   PubMed Web of Science ®Google Scholar
• Delaby C, Alcolea D, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep. 2020;10:9161.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhu Y, Hsiao‐Nakamoto J, Tang X, Dugas JC, Moscovitch‐Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103–16.
   PubMed Web of Science ®Google Scholar
• Thouvenot E, Demattei C, Lehmann S, Maceski‐Maleska A, Hirtz C, Juntas‐Morales R, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251–7.
   PubMed Web of Science ®Google Scholar
• Brodovitch A, Boucraut J, Delmont E, Parlanti A, Grapperon A-M, Attarian S, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11:703.
   PubMed Web of Science ®Google Scholar
• Gagliardi D, Faravelli I, Meneri M, Saccomanno D, Govoni A, Magri F, et al. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: a cross‐sectional study. J Cell Mol Med. 2021;25:3765–71.
   PubMed Web of Science ®Google Scholar
• Myzithras M, Li H, Bigwarfe T, Waltz E, Gupta P, Low S, et al. Development of an ultra-sensitive Simoa assay to enable GDF11 detection: a comparison across bioanalytical platforms. Bioanalysis 2016;8:511–8.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine (CCLM). 2016;54: 1655–61.
   Google Scholar
• Riva N, Iannaccone S, Corbo M, Casellato C, Sferrazza B, Lazzerini A, et al. Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann Neurol. 2011;69:197–201.
   PubMed Web of Science ®Google Scholar
• Gray E, Thompson AG, Wuu J, Pelt J, Talbot K, Benatar M, et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020; Aug7:1296–306.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Thézénas M-L, Charles PD, Evetts S, Hu MT, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis: CSF macrophage biomarkers in ALS. Ann Neurol. 2018; Feb83:258–68.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020; Jan139:119–34.
   PubMed Web of Science ®Google Scholar